These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 8388194

  • 1. Pharmacokinetics of rufloxacin in patients with impaired renal function.
    Perry G, Mant TG, Morrison PJ, Sacks S, Woodcook J, Wise R, Imbimbo BP.
    Antimicrob Agents Chemother; 1993 Apr; 37(4):637-41. PubMed ID: 8388194
    [Abstract] [Full Text] [Related]

  • 2. Multiple-dose pharmacokinetics of rufloxacin in patients with cirrhosis.
    Triger DR, Granai F, Woodcock J, Wise R, Imbimbo BP.
    Hepatology; 1993 Oct; 18(4):847-52. PubMed ID: 8406358
    [Abstract] [Full Text] [Related]

  • 3. Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers.
    Kisicki JC, Griess RS, Ott CL, Cohen GM, McCormack RJ, Troetel WM, Imbimbo BP.
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1296-301. PubMed ID: 1329618
    [Abstract] [Full Text] [Related]

  • 4. Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function.
    Leroy A, Fillastre JP, Humbert G.
    Antimicrob Agents Chemother; 1990 Jan; 34(1):17-20. PubMed ID: 2327756
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses.
    Mattina R, Bonfiglio G, Cocuzza CE, Gulisano G, Cesana M, Imbimbo BP.
    Chemotherapy; 1991 Jan; 37(6):389-97. PubMed ID: 1662127
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers.
    Imbimbo BP, Broccali G, Cesana M, Crema F, Attardo-Parrinello G.
    Antimicrob Agents Chemother; 1991 Feb; 35(2):390-3. PubMed ID: 2024974
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of sparfloxacin in patients with renal impairment.
    Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D.
    Antimicrob Agents Chemother; 1994 Apr; 38(4):733-7. PubMed ID: 8031038
    [Abstract] [Full Text] [Related]

  • 10. Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.
    Granneman GR, Braeckman R, Kraut J, Shupien S, Craft JC.
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2345-51. PubMed ID: 1666497
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent.
    Wise R, Johnson J, O'Sullivan N, Andrews JM, Imbimbo BP.
    J Antimicrob Chemother; 1991 Dec; 28(6):905-9. PubMed ID: 1667783
    [Abstract] [Full Text] [Related]

  • 12. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function.
    Nilsen OG, Saltvedt E, Walstad RA, Marstein S.
    Am J Med; 1992 Apr 06; 92(4A):38S-40S. PubMed ID: 1316068
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of rufloxacin in healthy volunteers.
    Segre G, Cerretani D, Moltoni L, Urso R.
    Eur J Clin Pharmacol; 1992 Apr 06; 42(1):101-5. PubMed ID: 1311685
    [Abstract] [Full Text] [Related]

  • 14. High performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites N-desmethylrufloxacin and rufloxacinsulfoxide in plasma and urine of humans.
    Vree TB, van den Biggelaar-Martea M, Imbimbo BP.
    Eur J Drug Metab Pharmacokinet; 1992 Apr 06; 17(1):45-9. PubMed ID: 1323466
    [Abstract] [Full Text] [Related]

  • 15. Steady-state pharmacokinetics of rufloxacin in elderly patients with lower respiratory tract infections.
    Cogo R, Rimoldi R, Mattina R, Imbimbo BP.
    Ther Drug Monit; 1992 Feb 06; 14(1):36-41. PubMed ID: 1312263
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of quinolones in renal insufficiency.
    Fillastre JP, Leroy A, Moulin B, Dhib M, Borsa-Lebas F, Humbert G.
    J Antimicrob Chemother; 1990 Oct 06; 26 Suppl B():51-60. PubMed ID: 2124213
    [Abstract] [Full Text] [Related]

  • 17. Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin.
    Lazzaroni M, Imbimbo BP, Bargiggia S, Sangaletti O, Dal Bo L, Broccali G, Bianchi Porro G.
    Antimicrob Agents Chemother; 1993 Oct 06; 37(10):2212-6. PubMed ID: 8257146
    [Abstract] [Full Text] [Related]

  • 18. Influence of renal function on the pharmacokinetics of lomefloxacin compared with other fluoroquinolones.
    Blum RA.
    Am J Med; 1992 Apr 06; 92(4A):18S-21S. PubMed ID: 1316065
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of temafloxacin in humans after multiple oral doses.
    Granneman GR, Carpentier P, Morrison PJ, Pernet AG.
    Antimicrob Agents Chemother; 1992 Feb 06; 36(2):378-86. PubMed ID: 1318680
    [Abstract] [Full Text] [Related]

  • 20. [Pharmacokinetic study of sparfloxacin in patients receiving regular hemodialysis].
    Aoki N, Kouda Y, Yoshikawa H, Usuda Y.
    Jpn J Antibiot; 1995 Aug 06; 48(8):999-1002. PubMed ID: 7474327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.